Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jeevan Scientific TechnologyBOM:538837 +1.17%65 EBITDA Margin % is 21.52% as of Mar. 2026, which is 14% above its 10-year median of 18.90. GuruFocus rates BOM:538837 with a GF Score™ of 65/100 and a GF Value™ of ₹61.75 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 940 Biotechnology companies, Jeevan Scientific Technology ranks better than 80.64% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jeevan Scientific Technology EBITDA Margin % Related Terms
Jeevan Scientific Technology EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:538837 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Jeevan Scientific Technology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeevan Scientific Technology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jeevan Scientific Technology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jeevan Scientific Technology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeevan Scientific Technology (BOM:538837) has a EBITDA Margin % of 21.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jeevan Scientific Technology and its competitors. This is 14% above median its historical median of 18.90. According to the industry distribution chart, Jeevan Scientific Technology ranks #182 out of 940 companies in the Biotechnology industry, placing it in the top 19.4%.
Is Jeevan Scientific Technology's EBITDA Margin % too high?
Jeevan Scientific Technology's current EBITDA Margin % of 21.52% is 14% above median its 10-year median of 18.90. Based on the distribution chart, Jeevan Scientific Technology ranks #182 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Jeevan Scientific Technology has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jeevan Scientific Technology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jeevan Scientific Technology ranks #182 out of 940 companies for EBITDA Margin %. This places Jeevan Scientific Technology in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jeevan Scientific Technology and its competitors. Jeevan Scientific Technology's current EBITDA Margin % is 21.52%, which is 14% above median its own 10-year median of 18.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeevan Scientific Technology stock overvalued right now?
Based on GuruFocus' analysis, Jeevan Scientific Technology (BOM:538837) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹61.75, compared to a current price of ₹72.77 — trading 17.8% above its estimated fair value. The current EBITDA Margin % is 21.52%, which is 14% above median its 10-year median of 18.90. Jeevan Scientific Technology's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jeevan Scientific Technology (BOM:538837), the current EBITDA Margin % is 21.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeevan Scientific Technology (BOM:538837) Overvalued in 2026?
Based on GuruFocus' analysis, Jeevan Scientific Technology stock appears to be overvalued.
The current stock price of ₹72.77 is trading 17.8% above its estimated GF Value™ of ₹61.75.
GuruFocus considers Jeevan Scientific Technology to be Modestly Overvalued.
Key valuation signals for BOM:538837:
EBITDA Margin %: 21.52% (14% above median its 10-year median of 18.90)
GF Value™: ₹61.75 vs. price of ₹72.77 (17.8% above fair value)
No single metric tells the full story. See the BOM:538837 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeevan Scientific Technology Ltd is an India-based company engaged in providing clinical research and data management services. Jeevan Scientific is an independent clinical contract research organization, offering reliable, cost-effective, and technology-driven clinical research solutions to various clients across the globe. Its services offer high-value testing services, including bioanalytical services for small and large molecules, ranging across generics, biosimilars, and other new drugs. It operates in a single segment, namely clinical research services.
65GF Score
Get the complete analysis for BOM:538837
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:538837 has been successfully added to your 
